Provectus Pharmaceuticals Inc. Receives Patent Allowance in the EU for PH-10 Dermatology Agent

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has received allowance of its patent application in the European Union covering its lead dermatology agent, PH-10, along with a number of related agents and their use. Provectus has also received allowance of another patent application in Canada covering applicator devices used with PH-10 and related agents. The pending patents cover topical products for treatment of skin diseases such as psoriasis and eczema, along with certain medical devices for application of PH-10 to internal surfaces of the body.

Back to news